The model for end-stage liver disease (MELD)

Area of Science:

• Hepatology
• Transplantation Medicine
• Medical Informatics

Background:

• The Model for End-stage Liver Disease (MELD) was developed to predict survival in patients undergoing specific procedures for portal hypertension.
• MELD has been validated as an accurate predictor of survival across diverse patient groups with advanced liver disease.
• Its primary application is in organ allocation for liver transplantation.

Purpose of the Study:

• To review the established uses and predictive capabilities of the MELD score.
• To explore the limitations of the MELD score in predicting survival for a subset of patients.
• To suggest potential avenues for improving the MELD score's accuracy.

Main Methods:

• Review of existing literature and validation studies on the MELD score.
• Analysis of MELD score's application in various clinical scenarios beyond liver transplantation.
• Identification of patient populations where MELD score's predictive accuracy is limited.

Main Results:

• MELD score accurately predicts survival in patients with advanced liver disease, including those with infections, variceal bleeding, fulminant hepatic failure, and alcoholic hepatitis.
• MELD score is utilized for organ allocation, surgical patient selection, and treatment planning for hepatocellular carcinoma.
• Approximately 15%-20% of patients exhibit survival predictions that are not accurately captured by the current MELD score.

Conclusions:

• The MELD score is a valuable tool in managing patients with advanced liver disease and in liver transplant allocation.
• Enhancing the MELD score with additional biomarkers of liver and renal function may improve its predictive accuracy.
• Continued efforts in refining and validating the MELD score are essential for optimizing patient care.